Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies
January 03, 2019 at 14:18 PM EST
Bristol Myers-Squibb is acquiring Celgene in a cash and stock deal valued at $74 billion. Some view the deal as an act of survival.